Leukemia Physician at MD Anderson. Research in AML, CML, other leukemias if it's the right genotype. Views expressed here are my own.
Joined April 2017
- Tweets 153
- Following 297
- Followers 781
- Likes 109
4 Photos and videos
Pinned Tweet
15 Mar 2023
Surreal to play a role in this relay race. Below proof that menin inhibition works. A new targeted therapy in leukemia published @Nature
nature.com/articles/s41586-0โฆ @MDAndersonNews
30
69
253
58,042
Ghayas Issa retweeted
22 Nov 2024
Menin inhibitors emerge as new treatment for advanced AML. Guest editorial by Ghayas Issa (@GhayasIssa, @MDAndersonNews).
cancerletter.com/trials-and-โฆ
5
17
1,303
Ghayas Issa retweeted
18 Nov 2024
"Our research confirmed the significant benefits and efficacy of this therapy for both adult and pediatric patients," says Dr. Ghayas Issa.
@US_FDA has approved revumenib for some patients with relapsed or refractory acute leukemia: brnw.ch/21wOL2U @GhayasIssa #EndCancer
ALT "The recent FDA approval of revumenib is a major step forward." Ghayas Issa, M.D. Physician & Researcher
1
13
45
4,359
15 Nov 2024
Menin inhibition is a standard of care! FDA approval of revumenib!! So happy to see that the benefit witnessed in patients on study is leading to a medicine to all who need it. Ready to forj ahead with more to come! ;)
11
38
184
20,673
Ghayas Issa retweeted
Weโve enrolled the first patient in a phase 2 clinical trial targeting minimal residual disease in #AML, hoping to prevent relapse by eliminating lingering cancer cells. #RadicalCollaboration
@GhayasIssa @MDAndersonNews
4
9
9,442
5 Nov 2024
The first BTC trial to target AML MRD with combination of menin and BCL2 inhibition is now open! Huge team effort and more exciting trials for MRD to come. Goal is to better measure, understand and treat MRD
Weโve enrolled the first patient in a phase 2 clinical trial targeting minimal residual disease in #AML, hoping to prevent relapse by eliminating lingering cancer cells. #RadicalCollaboration
@GhayasIssa @MDAndersonNews
4
12
51
7,783
Ghayas Issa retweeted
24 Aug 2024
Menin Inhibition With Revumenib for KMT2A-Rearranged
Relapsed or Refractory Acute #Leukemia (AUGMENT-101): brnw.ch/21wM2Yh #leusm
5
8
2,245
9 Aug 2024
Revumenib phase 2 for R/R KMT2Ar finally out! ORR 63%, CR/CRh 23%, MRD neg 70%. Result filed for FDA approval
ascopubs.org/doi/10.1200/JCOโฆ
8
44
113
13,501
Ghayas Issa retweeted
1 Aug 2024
How long do you wait for leukemia fusion RT-PCR, FISH, cytogenetics? Bedside CRISPR-based detection of PML::RARA and BCR::ABL1 fusions as a point of care test, even on a dried blood spot, from #RahulVedula and @ColemanLindsley @DanaFarber #HemeNeoDivision ashpublications.org/blood/arโฆ
2
11
48
4,041
9 Jul 2024
A pleasure to do this on differentiation syndrome with Eytan and Courtney. A thread ๐งต
ashpublications.org/blood/arโฆ
2
12
64
5,527
Ghayas Issa retweeted
21 Jun 2024
Menin inhibitors seek to debut as newest targeted therapy for leukaemia bit.ly/3xsRP99
Find out how small molecules that block a key proteinโprotein interaction could change the treatment landscape for many patients with acute leukaemias in this news article
4
10
1,960
Ghayas Issa retweeted
19 Jun 2024
๐๐Delighted to present results of an investigator-initiated trial of Pirto Ven Obin as firstline Rx of pts with #CLL at @EHA_Hematology #EHA2024
A thread ๐งต
3
16
72
14,366
31 May 2024
Asciminib frontline!
Presented at #ASCO24:
ASC4FIRST: Asciminib, an agent that targets the myristoyl pocket of BCR::ABL, was compared with imatinib and with imatinib plus second-generation tyrosine kinase inhibitors. Outcomes were better with aciminib in both comparisons. nej.md/4bNNr3c
ALT The cumulative incidence of major molecular response for asciminib and imatinib (imatinib full analysis set).
5
21
2,592
19 Apr 2024
Nice! Congrats @DavidSeoMD!! Forgive you for missing eclipse events :)
19 Apr 2024
Watch author @DavidSeoMD discuss his research article, Randomized phase 1b microbiome modulation trial in #melanoma, published simultaneously at #AACR24:
vimeo.com/932607668/63addff7โฆ
@MDAndersonNews
1
3
855
Ghayas Issa retweeted
19 Apr 2024
Watch author @DavidSeoMD discuss his research article, Randomized phase 1b microbiome modulation trial in #melanoma, published simultaneously at #AACR24:
vimeo.com/932607668/63addff7โฆ
@MDAndersonNews
8 Apr 2024
Just published with the #AACR24 presentation, by @DavidSeoMDโ
Randomized Placebo-Controlled, Biomarker-stratified Phase 1b #Microbiome Modulation in #Melanoma: Impact of Antibiotic Pre-conditioning.
bit.ly/4cIDANr
@CSpencerPhD @JenWargoMD @MDAndersonNews
3
4
8,168
22 Feb 2024
Wonderful editorial by Dr Bernt on Barajas et al showing the latest addition to the โclubโ. Eytan and I have been brewing this trial for a while and itโs finally about to open: menin inhibition for the HOX-high club (including UBTF-TD based on this work)
classic.clinicaltrials.gov/cโฆ
1
2
16
6,898
10 Dec 2023
5
624
Ghayas Issa retweeted
9 Dec 2023
Menin inhibitors continue to show tremendous promise in AML w/ encouraging clinical activity as single agents and now in comb. w/ HMAโs Ven in R/R AML w/ NPM1 or KMT2Ar. Great presentation by @GhayasIssa on SAVE trial. Hopeful these agents will make a huge impact in AML. #ASH23
11
45
2,981
Ghayas Issa retweeted
9 Dec 2023
Revumenib Combo Showcases Early Activity in Relapsed/Refractory AML @GhayasIssa @MDAndersonNews @ASH_Hematology #ASH23 #ASH2023 #leusm onclive.com/view/revumenib-cโฆ
1
1
10
1,510